glp-1 and thyroid issues Dual Glucagon-Like Peptide-1 (GLP-1) Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonist-Associated Thyroiditis: A Case Report of Dysfunction Following Tirzepatide Use GLP-1 Medications & Thyroid Disease

The estimated proportion of participants who achieved at least 5% weight loss was 40.4%-88.8% in the low- and high-dose groups, compared with 15.6% in the placebo group

healthcare system, and contributing to the health of our nation for generations to come

According to UAB clinicians, patients are presenting with dangerously low blood sugar, severe nausea, and pancreatitisoften the result of unsupervised use or improper titration

For the future, we hope GLP-1- based drugs together with antithrombotic medications can be a promising field to improve prevention and management of coronary events, also in nondiabetic patients, resulting in reduced mortality in patients with CAD

doi: 10.1152/physiol.2024.39.S1.508 Zhang Q, Liu C, Shi R, et al